Subscribe To

Price Alert Latest News Economic Calendar News

SGMO / Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago. Read More

Demo Live Account See Partner Details

Content Topics

Sangamo

Therapeutics

SGMO

Reports

Loss

Misses

Revenue

sgmo

Estimates

Stock

Posted: Aug 8 2023, 18:56

Author Name: Zacks Investment Research

Views: 111991

SGMO News

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

By Business Wire
October 24, 2023

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (E

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg R

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.